|
Q3 FY2026
As of Sep 30, 2026
|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current assets: | ||||||||||||
| Short-term investments | ||||||||||||
| Cash and cash equivalents | ||||||||||||
| Short-term investments at fair value | ||||||||||||
| Short-term investment at cost | ||||||||||||
| Accounts Receivable, after Allowance for Credit Loss, Current | ||||||||||||
| Related party accounts receivable | ||||||||||||
| Inventories | ||||||||||||
| Note receivable | ||||||||||||
| Prepaid inventory | ||||||||||||
| Other current assets | ||||||||||||
| Total current assets | ||||||||||||
| Property and equipment, net | ||||||||||||
| Deferred offering costs | ||||||||||||
| Operating lease right-of-use asset | ||||||||||||
| Goodwill and intangible assets | ||||||||||||
| Other assets | ||||||||||||
| Goodwill | ||||||||||||
| Intangible assets, net | ||||||||||||
| Unallocated purchase price provisional, Rotor Lab (See note 3) | ||||||||||||
| Total non-current assets | ||||||||||||
| Total assets | ||||||||||||
| Current liabilities | ||||||||||||
| Accounts payable and accrued expenses | ||||||||||||
| Deferred revenue | ||||||||||||
| Warrant liabilities | ||||||||||||
| Derivative liability – convertible note conversion option | ||||||||||||
| Operating lease liability | ||||||||||||
| Contingent consideration | ||||||||||||
| Total current liabilities | ||||||||||||
| Convertible note | ||||||||||||
| Deferred tax liability | ||||||||||||
| Operating lease liability – less current portion | ||||||||||||
| Contingent consideration | ||||||||||||
| Total non-current liabilities | ||||||||||||
| Total liabilities | ||||||||||||
| Preferrred stock, value | ||||||||||||
| Series A Preferred Stock | ||||||||||||
| Series B Preferred Stock | ||||||||||||
| Series C Preferred Stock | ||||||||||||
| Total preferrred stock, value | ||||||||||||
| Common stock - $0.01 par value, 500,000,000 authorized and 49,982,430 and 37,759,911 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively | ||||||||||||
| Additional paid in capital | ||||||||||||
| Accumulated deficit | ||||||||||||
| Cumulative foreign currency translation adjustment | ||||||||||||
| Accumulated other comprehensive income | ||||||||||||
| Total stockholders’ equity | ||||||||||||
| Total liabilities and stockholders’ equity |
Loading...